EU steps up threat to block vaccine exports to UK amid row over shortages

Millions of doses could be stopped from reaching Britain
PA

Brussels is set to outline its plan for vaccine exports which could see millions of doses blocked from entered the UK amid a row over shortages in member states.

The EU’s fight to secure jabs intensified when the bloc warned drug firms such as AstraZeneca it would use all “legal means” or even block exports unless they agreed to deliver shots.

The European Commission is expected later on Friday to lay out the criteria under which such exports would be evaluated, with could impact supplies arriving in Britain.

Meanwhile, UK phase three trials of the Novavax Covid-19 vaccine have found it demonstrated 89.3 per cent efficacy against the virus. The vaccine candidate was found to be 95.6 per cent effective against the original strain and 85.6 per cent effective against emerging variants.

The bloc is scrambling to get supplies just as the West’s biggest drugmakers slow deliveries to the bloc due to production problems. As vaccination centres in Germany, France and Spain cancelled or delayed appointments, the EU publicly rebuked Anglo-Swedish drugmaker AstraZeneca for failing to deliver.

European Council President Charles Michel said in a letter to four EU leaders that the EU should explore all legal means to ensure supplies of vaccines it contracted to buy, if negotiations are unsuccessful.

“If no satisfactory solution can be found, I believe we should explore all options and make use of all legal means and enforcement measures at our disposal under the Treaties,” he said in the letter.

Coronavirus - In pictures

1/80

EU rules on monitoring and authorising exports of  Covid vaccines in the 27-nation bloc could lead to exports being blocked if they violated existing contracts between the vaccine maker and the EU, an EU official said.

The global mass vaccination is stoking tensions across the world as big powers buy up doses in bulk and poorer nations try to collect whatever supplies are left.

Israel is by far the world leader on vaccine rollout per head of population, followed by the United Arab Emirates, the UK, Bahrain and the US. Behind them are Italy, Germany, France, China and Russia.

Both New York-based Pfizer and AstraZeneca, headquartered in Cambridge, England, have had production problems.

AstraZeneca CEO Pascal Soriot said the EU was late to strike a supply contract so the company did not have enough time to iron out production problems at a vaccine factory run by a partner in Belgium.

The European Commission has asked Belgian authorities to inspect production at the plant, Belgium’s Federal Agency for Medicines and Health Products (FAGG) said on Thursday.

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in